- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05700903
Contributions to Hypertension With Androgen Deprivation Therapy (ARCH)
November 14, 2023 updated by: University of Colorado, Denver
Autonomic and Renal Contributions to Hypertension With Androgen Deprivation Therapy
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer.
Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT.
However, ADT increases the likelihood of developing heart disease including high blood pressure.
This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure.
The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
228
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Matthew Babcock, PhD
- Phone Number: 303-724-1401
- Email: matthew.babcock@cuanschutz.edu
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- UCHealth University of Colorado Hospital
-
Contact:
- Matthew Babcock, PhD
- Phone Number: 720-848-6470
- Email: matthew.babcock@cuanschutz.edu
-
Principal Investigator:
- Matthew Babcock, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- -age 40+ years;
- resting blood pressure <140/90 mmHg;
- fasted blood glucose <126 mg/dL;
- testosterone ≥400 ng/dL;
- sedentary to recreationally active;
- nonsmokers;
- healthy as determined by medical history, physical exam, blood and urine chemistries and resting and exercise ECG during a physician supervised graded exercise treadmill test OR recent diagnosis of non-metastatic prostate cancer with plans to undergo androgen deprivation therapy;
- PSA <4.00 ng/dL if in the non-cancer group;
- Gleason Score ≤7 if in the prostate cancer group;
- no use of medications that might influence cardiovascular function (e.g., antihypertensives, lipid-lowering medications);
- willing and able to be on GnRHagonist and AR inhibitor;
- not taking antioxidant vitamins, corticosteroids, or anti-inflammatory medications, or willing to stop use for four weeks prior to the start of the study;
- not using exogenous sex hormones for at least one year
Exclusion Criteria:
- -acute liver disease;
- chronic kidney disease, serum creatinine >1.3 mg/dL, macroalbuminuria >300 mg/g of proteinuria
- pre-existing or active cardiac, renal or hepatic disease, epilepsy or other seizure disorder;
- diabetes, active or chronic infection, disease that affects the nervous system;
- Gleason Score ≥8;
- thyroid dysfunction, defined as ultrasensitive TSH <0.5 or >5.0 mU/L, volunteers with abnormal TSH values will be re-considered for participation after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement;
- tobacco use within the previous 12 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Prostate Cancer
Men undergoing androgen deprivation therapy via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for the treatment of prostate cancer
|
8 weeks of GnRH agonist
Other Names:
2 weeks of AR Inhibitor
Other Names:
|
Active Comparator: Healthy + ADT
Healthy men undergoing gonadal suppression via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for 9 weeks
|
8 weeks of GnRH agonist
Other Names:
2 weeks of AR Inhibitor
Other Names:
|
Placebo Comparator: Healthy + Placebo
Healthy men undergoing placebo for 9 weeks.
|
Placebo tablet and injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Cardiovagal Baroreflex Sensitivity
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
The change in cardiovagal baroreflex sensitivity will be assessed the modified Oxford procedure
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Change in blood pressure reactivity to the cold pressor test
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
The change in blood pressure will be assessed from quiet rest to sympathetic activation using the cold pressor test
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Change in exercise pressor reflex
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
The change in blood pressure will be assessed from quiet rest to isometric handgrip exercise
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Change in ambulatory blood pressure variability
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
Ambulatory blood pressure variability will be determined from 24-hour ambulatory blood pressure monitoring.
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Change in beat-to-beat blood pressure variability
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
Beat-to-beat blood pressure variability will be using finger photoplethysmography measured in the laboratory.
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Change in renal vascular resistance
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
Renal blood flow will be determined using ultrasound and blood pressure will be determined using finger photoplethysmography.
These measures will be used to estimate renal vascular resistance.
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Change in Renal dysfunction biomarkers
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
Neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule (KIM)-1, interleukin (IL)-18, and vanin-1 will be quantified in urine using commercially available assay kits.
Concentrations will be normalized to urinary flow rate.
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in sympathetic baroreflex sensitivity
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
Changes in muscle sympathetic nerve activity in response to changes in blood pressure will be assessed using the modified Oxford procedure
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Change in Sympathetic reactivity
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
The change in muscle sympathetic nerve activity will be assessed from quiet rest to sympathetic activation using the cold pressor test.
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Change in glomerular filtration rate
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
Glomerular filtration rate and renal plasma flow will be calculated by iohexol (Omnipaque 300, GE Healthcare) clearance technique.
Plasma and urine iohexol and p-aminohippurate clearance will be measured on a High-Performance Liquid Chromatography (HPLC, Waters, Milford, MA).
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Change in renal plasma flow
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
Renal plasma flow will be calculated by p-aminohippurate (Basic Pharma) clearance techniques.
Plasma and urine p-aminohippurate clearance will be measured on a High-Performance Liquid Chromatography (HPLC, Waters, Milford, MA).
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Inflammation
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
Proteomic analysis of inflammatory cascade proteins will be quantified in plasma samples.
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Change in Oxidative stress
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
Whole blood reactive oxygen species will be measured in from venous blood samples using electron paramagnetic resonance spectroscopy
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Change in Body composition
Time Frame: Before and after 9 weeks of androgen deprivation therapy or placebo
|
Descriptive variable total body fat mass (for screening and to document any changes with the intervention)
|
Before and after 9 weeks of androgen deprivation therapy or placebo
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Matthew Babcock, PhD, University of Colorado - Anschutz Medical Campus
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 20, 2023
Primary Completion (Estimated)
March 31, 2028
Study Completion (Estimated)
March 31, 2028
Study Registration Dates
First Submitted
January 10, 2023
First Submitted That Met QC Criteria
January 18, 2023
First Posted (Actual)
January 26, 2023
Study Record Updates
Last Update Posted (Estimated)
November 17, 2023
Last Update Submitted That Met QC Criteria
November 14, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Hypertension
- Primary Dysautonomias
- Autonomic Nervous System Diseases
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Androgen Antagonists
- Leuprolide
- Goserelin
- Hormones
- Bicalutamide
- Androgens
- Flutamide
- Androgen Receptor Antagonists
Other Study ID Numbers
- 22-2201.cc
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Gonadotropin-Releasing Hormone Agonist
-
Tanta UniversityCompletedInfertility | Intracytoplasmic Sperm Injection | Ovarian Reserve | GnRH AgonistEgypt
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
Rabin Medical CenterPfizerCompleted
-
Kuban State Medical UniversityActive, not recruiting
-
Umeå UniversityKarolinska University Hospital; Vastra Gotaland Region; Region Jönköping County; Region Skane and other collaboratorsRecruitingProstate Cancer Metastatic | Positron-Emission Tomography | Radiation TherapySweden
-
Ginegorama S.L.UnknownInfertility, Female | Ovulation Induction | In Vitro Fertilization (IVF) | OocytesSpain
-
Nova Clinic, RussiaUnknownInfertility, Female | Ovarian Stimulation | In Vitro FertilisationRussian Federation
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.A.S, FranceTerminated
-
Assiut UniversityUnknownInfertility, Female